Read by QxMD icon Read

Montelukast biomarker

Susan Lu, Tina V Hartert, Mark L Everard, Hilde Giezek, Linda Nelsen, Anish Mehta, Hima Patel, Barbara Knorr, Theodore F Reiss
BACKGROUND: We sought to identify predictors of asthma development following severe early childhood RSV bronchiolitis. Different definitions of asthma were also compared. METHODS: This longitudinal, observational study (N = 343) followed patients (<2 years old) from a placebo-controlled trial (N = 979) of montelukast after RSV bronchiolitis to identify clinical, demographic, or biochemical predictors of asthma, atopic disorders, and chronic asthma therapy use at 6 years of age (Clinical Trials Registry Number: NCT01140048)...
May 6, 2016: Pediatric Pulmonology
You Hoon Jeon, Taek Ki Min, Hyeon Jong Yang, Bok Yang Pyun
PURPOSE: Some studies report a role of leukotrienes in the pathogenesis of atopic dermatitis and suggest a rationale for the use of leukotriene receptor antagonist (LTRA) in the treatment of atopic dermatitis. This study aimed to evaluate the treatment effectiveness of montelukast in children with atopic dermatitis. METHODS: Fifty-four children between the ages of 2 and 6 years with moderate to severe atopic dermatitis were enrolled. Group A received montelukast for 8 weeks, followed by a crossover to 8 weeks of placebo after a 2-week washout period...
July 2016: Allergy, Asthma & Immunology Research
Andrew Bush
Leukotriene receptor antagonists were introduced as an entirely new concept in asthma therapy, which indeed they are. However, although an intellectually new concept, they have largely disappointed in clinical practice. A small minority of school age asthmatics may respond better to these medications as against inhaled corticosteroids as prophylactic therapy. In children not responding to low dose inhaled corticosteroids, the best add-on therapy is salmeterol, but a small number respond better to Montelukast...
March 2015: Paediatric Respiratory Reviews
M A Saad, R M Abdelsalam, S A Kenawy, A S Attia
Cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory and immune modulating lipid mediators involved in inflammatory diseases and were boosted in human brain after acute phase of cerebral ischemia. The antagonism of CysLTs receptors may offer protection against ischemic damage. Therefore it seemed interesting to study the possible neuroprotective effect of Montelukast, a CysLTR1 antagonist in global cerebral ischemia/reperfusion (IR) injury in rats. Global cerebral ischemia-reperfusion was induced by bilateral carotid artery occlusion for 15 min followed by 60 min reperfusion period...
January 2015: Neurochemical Research
David B Peden, Robert K Bush
In this review of articles published in the Journal in 2013, we report on the significant advances in environmental and occupational disorders. Research advances have led to the identification and defined the structure and function of several major allergens. A meta-analysis confirmed the importance of mold exposure in patients with allergic rhinitis, and a new immunologic classification of aspergillosis emerged. Insights into the role of diesel exhaust particles in patients with severe asthma were clarified...
May 2014: Journal of Allergy and Clinical Immunology
Ramneet Gill, Sankaran Krishnan, A J Dozor
OBJECTIVE: The effects of low-level environmental tobacco smoke (ETS) exposure, on asthma control, lung function and inflammatory biomarkers in children with asthma have not been well studied. The objective of the study was to assess ETS exposure in school-age children with asthma whose parents either deny smoking or only smoke outside the home, and to assess the impact of low-level ETS exposure on asthma control, spirometry and inflammatory biomarkers. METHODS: Forty patients age 8-18 years with well-controlled, mild-to-moderate persistent asthma treated with either inhaled corticosteroids (ICS) or montelukast were enrolled...
May 2014: Journal of Asthma: Official Journal of the Association for the Care of Asthma
Neil G Snowise, Diane Clements, Shu-Yen Ho, Richard M A Follows
OBJECTIVE: To investigate the clinical benefits of 'add-on' therapy with GSK2190915 in combination with the inhaled corticosteroid (ICS) fluticasone propionate (FP) and the ICS/long-acting beta 2 agonist (LABA) combination FP/salmeterol in asthmatic subjects. METHODS: Both studies were cross-over, randomized, double-blind, double-dummy and placebo-controlled in subjects with a forced expiratory volume in 1 second (FEV1) best of >50 and ≤80% of predicted. Add-on to ICS: Subjects (n = 162) aged ≥12 years received FP 100 µg twice daily (BID) plus GSK2190915 100 mg once daily (QD); GSK2190915 300 mg QD; montelukast 10 mg QD; salmeterol 50 µg BID or placebo...
December 2013: Current Medical Research and Opinion
Elena García-Martín, Gabriela Canto, José A G Agúndez
INTRODUCTION: The clinical management of allergic diseases involves a number of drugs, most of which are extensively metabolized. This review aims to analyze the metabolism and the clinical implications of altered metabolism for these drugs. AREAS COVERED: The authors present an overview of current knowledge of the metabolism of: antihistamine drugs, glucocorticoids, inhaled β-2 bronchodilators, anticholinergics and other drugs used in allergic diseases, such as cromoglycate, omalizumab, montelukast and epinephrine...
November 2013: Expert Opinion on Drug Metabolism & Toxicology
M Zedan, G Attia, M M Zedan, A Osman, N Abo-Elkheir, N Maysara, T Barakat, N Gamil
Asthma is a heterogeneous disease that means not all asthmatics respond to the same treatment. We hypothesize an approach to characterize asthma phenotypes based on symptomatology (shortness of breath (SOB), cough, and wheezy phenotypes) in correlation with airway inflammatory biomarkers and FEV1. We aimed to detect whether those clinical phenotypes have an impact on the response to asthma medications. Two hundred three asthmatic children were allocated randomly to receive either montelukast (5 mg at bed time) or fluticasone propionate (100 ug twice daily) for 8 consecutive weeks...
2013: ISRN Pediatrics
André Schultz, Paul L P Brand
Accumulating evidence suggest that splitting preschool recurrent wheezing disorders into Episodic (Viral) Wheeze (EVW) and Multiple Trigger Wheeze (MTW) is an oversimplification. There is little evidence that the EVW and MTW phenotypes are related to the longitudinal patterns of wheeze, or to different underlying pathological processes. As the clinical response to inhaled corticosteroids and montelukast varies considerably between individual children with EVW, and between individual patients with MTW, the clinical usefulness of the EVW-MTW approach is doubtful...
September 2011: Paediatric Respiratory Reviews
Ahmed M Mohamadin, Ahmed A Elberry, Mohamed A Elkablawy, Hala S Abdel Gawad, Fahad A Al-Abbasi
Endotoxemia-induced hepatotoxicity is characterized by disturbed intracellular redox balance, excessive reactive oxygen species (ROS) generation inducing DNA, proteins and membrane lipid damages. In the present study, the protective effects of montelukast (MNT) against Escherichia coli lipopolysaccharides (LPS)-induced oxidative stress were investigated in rat liver. LPS (10mg/kg, i.p.) was injected and the animals were sacrificed 6h after LPS challenge. MNT (10mg/kg) was administered orally for seven successive days before endotoxemia induction...
June 2011: Pathophysiology: the Official Journal of the International Society for Pathophysiology
Sandra Tecklenburg-Lund, Timothy D Mickleborough, Louise A Turner, Alyce D Fly, Joel M Stager, Gregory S Montgomery
BACKGROUND: Both fish oil and montelukast have been shown to reduce the severity of exercise-induced bronchoconstriction (EIB). The purpose of this study was to compare the effects of fish oil and montelukast, alone and in combination, on airway inflammation and bronchoconstriction induced by eucapnic voluntary hyperpnea (EVH) in asthmatics. METHODS: In this model of EIB, twenty asthmatic subjects with documented hyperpnea-induced bronchoconstriction (HIB) entered a randomized double-blind trial...
2010: PloS One
Stefan Zielen, Martin Christmann, Magdalena Kloska, Gülben Dogan-Yildiz, Adrian Lieb, Martin Rosewich, Ralf Schubert, Markus A Rose, Johannes Schulze
BACKGROUND: Currently available anti-inflammatory treatment for young children with asthma includes inhaled corticosteroids (ICS) and the leukotriene receptor antagonist (LTRA) montelukast. OBJECTIVE: To evaluate potential biomarkers of predicting short-term (6-week) response to ICS and LTRAs in children with asthma. METHODS: A total of 102 children aged 4 to 7 years with episodic asthma were enrolled in an open labelled single-centre study...
February 2010: Current Medical Research and Opinion
Esther L Langmack, Richard J Martin
PURPOSE OF REVIEW: Patients with asthma exhibit heterogeneous responses to all classes of asthma medication. This review examines clinical characteristics, biomarkers of inflammation, and genetic polymorphisms associated with treatment responsiveness in studies of adults and children with asthma, with an emphasis on inhaled corticosteroids and leukotriene modifiers. RECENT FINDINGS: Recent clinical studies extended previous observations of associations between biomarkers of allergic inflammation and responsiveness to inhaled corticosteroids, and between cigarette smoke exposure and responsiveness to montelukast...
January 2010: Current Opinion in Pulmonary Medicine
Ronina A Covar, Stanley J Szefler, Robert S Zeiger, Christine A Sorkness, Mark Moss, David T Mauger, Susan J Boehmer, Robert C Strunk, Fernando D Martinez, Lynn M Taussig
BACKGROUND: Asthma exacerbations are a common cause of critical illness in children. OBJECTIVE: To determine factors associated with exacerbations in children with persistent asthma. METHODS: Regression modeling was used to identify historical, phenotypic, treatment, and time-dependent factors associated with the occurrence of exacerbations, defined by need for oral corticosteroids or emergency or hospital care in the 48-week Pediatric Asthma Controller Trial study...
October 2008: Journal of Allergy and Clinical Immunology
Arthur F Gelb, Colleen Flynn Taylor, Chris M Shinar, Carlos A Gutierrez, Noe Zamel
BACKGROUND: Monitoring noninvasive biomarkers of inflammation is an important adjunct in asthma therapy. OBJECTIVE: The goal of the present study was to identify airway and alveolar site(s) of inflammation using exhaled nitric oxide (NO) as a marker in asthmatic patients, and to evaluate the NO response to maintenance fluticasone 250 microg/salmeterol 50 microg (F/S) and add-on montelukast 10 mg (M). METHODS: Thirty (24 women) nonsmoking, mild to moderate asthmatic patients were studied, mean age (+/- SD) 43+/-9 years, treated with F/S for more than one year...
May 2008: Canadian Respiratory Journal: Journal of the Canadian Thoracic Society
Yasemin Ersoy, Esra Cikler, Sule Cetinel, Göksel Sener, Feriha Ercan
We investigated the role of montelukast (ML), a cysteinyl leukotriene-1 receptor antagonist, on the water avoidance stress (WAS)-induced degeneration of the rat gastric, ileal and colonic mucosa. One group of Wistar albino rats were exposed to chronic WAS (WAS group) 2h daily for 5 days. Another group was administered ML (10mg/kg; i.p.; WAS+ML group) following every WAS exposure for 5 days. Control rats were injected with the vehicle solution only. The stomach, ileum and colon were dissected and investigated for histopathological changes with a light microscope as well as for topographical changes with a scanning electron microscope...
March 2008: Prostaglandins, Leukotrienes, and Essential Fatty Acids
Hooman Allayee, Jaana Hartiala, Won Lee, Margarete Mehrabian, Charles G Irvin, David V Conti, John J Lima
BACKGROUND: Recent studies have implicated the 5-lipoxygenase/leukotriene (LT) pathway in cardiovascular disease (CVD), which may have important implications for asthmatics because several drugs that target this pathway are currently used to treat asthma. We sought to determine whether montelukast, a cysteinyl LT antagonist, and low-dose theophylline affected serum inflammatory and lipid CVD risk factors in a recently completed clinical trial in asthmatic patients. METHODS: Patients were randomized to receive either montelukast (10 mg/d), theophylline (300 mg/d), or placebo...
September 2007: Chest
Chang Cai, Jiong Yang, Suping Hu, Meiqian Zhou, Wei Guo
The aim of this study was to investigate and identify the relationship between urinary cysteinyl leukotriene E(4) levels and clinical response to antileukotriene treatment in patients with asthma. Forty-eight patients with stable mild to moderate asthma were treated with montelukast in a four-week trail. Asthmatic symptom score, beta(2)-agonist usage, percentage of eosinophil, total serum IgE concentration, forced expiratory volume in the first second (FEV(1)), peak expiratory flow rate (PEFR), and urinary leukotriene E(4) (uLTE(4)) were measured before and after treatment...
March 2007: Lung
Graeme P Currie, Kris McLaughlin
OBJECTIVE: To provide a comprehensive review of studies that evaluate the effects of leukotriene receptor antagonists in adult chronic asthma. DATA SOURCES: A literature search using MEDLINE, Clinical Evidence, and the Cochrane Library was performed using the following keywords: randomized controlled trial, asthma, cysteinyl leukotriene, leukotriene receptor antagonist, antileukotriene, montelukast, zafirlukast, pranlukast, inflammation, lung function, exacerbations, and symptoms...
December 2006: Annals of Allergy, Asthma & Immunology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"